drugset / Trial / NCT02492516

Intravenous Injection of Adipose Derived Mesenchymal Stem Cell for ALS

NCT02492516

Phase 1 Completed 19 enrolled Royan Institute
NaSingle-groupOpen-labelTreatment

Summary

Amyotrophic lateral sclerosis (ALS) is a lethal degenerative disorder that upper motor and lower motor neurons are destroyed in brain stem and spinal cord. Riluzole is the only therapeutic option now. Recently several studies have shown that stem cell transplantation is safe and can be effective in reduction of disease progression and increase of quality of life.

Timeline

Start
2014-09
Primary completion
2017-03
Completion
2017-04

Drugs

EvaluationDrugModalityDoseRoute
Subject mesenchymal stem cells Cell therapy 2e+06 cells/kg Intravenous